Stockreport

Immunovant Inc (IMVT) Reports Fiscal Q3 Results: Expands Clinical Programs Amid Rising R&D Costs [Yahoo! Finance]

Immunovant, Inc.  (IMVT) 
PDF R&D Expenses : R&D expenses increased to $48.3 million for the quarter, reflecting heightened activity in the development of IMVT-1402 and batoclimab. Net Loss : The [Read more]